i. biographical data name robert paul myers...

Last update: October 8, 2015

I. BIOGRAPHICAL DATA

Name ROBERT PAUL MYERS

Nickname ROB

Affiliated addresses University of Calgary, Teaching Research and Wellness Building Heritage Medical Research Clinic (HMRC) 3280 Hospital Drive, NW, 5th floor, room 5E13

Division of Gastroenterology and Hepatology (GI Division) 3280 Hospital Drive, NW, 6th floor, room 6D22 Calgary, AB, Canada, T2N 4Z6

Telephone HMRC: (403) 210-3800

GI Division: (403) 592-5049

Fax HMRC: (403) 270-3141 GI Division: (403) 592-5090

Email [email protected]

Present Rank Associate Professor of Medicine II. ACADEMIC RECORD

Final Degree Doctor of Medicine (MD) Date completed June 30, 1996 Specialties Internal Medicine, Gastroenterology, Hepatology Institution/City/Country University of Western Ontario, London, Ontario

i. Undergraduate Bachelor of Science (BSc) (Summa Cum Laude) Biochemistry − 1992 McMaster University, Hamilton, Ontario

ii. Professional Doctor of Medicine − 1996

University of Western Ontario, London, Ontario

Internal Medicine Residency − July 1996 - June 1999 University of Western Ontario, London, Ontario Chief Medical Resident - July 1998 – June 1999

Gastroenterology Fellowship − July 1999 - June 2001 University of Calgary, Calgary, Alberta

Hepatology Research Fellowship − July 2001 – Dec. 2002 Supervisor : Professor Thierry Poynard Groupe Hospitalier Pitié-Salpêtrière Université de Paris VI, Paris, France

Robert P. Myers Curriculum Vitae 2

Last updated: October 8, 2015

iii. Postgraduate Master of Science (MSc Epidemiology)

Master’s program Department of Community Health Sciences University of Calgary, Calgary, Alberta September 2008 Completed courses:

MDSC 644 (Introduction to Community Health Sciences) MDSC 643.01 (Biostatistics I) MDSC 643.02 (Biostatistics II) MDSC 743 (Biostatistics III) MDSC 647.01 (Fundamentals of Epidemiology) MDSC 659.02 (Health Research Methods) MDSC 659.04 (Introduction to Clinical Trials)

Thesis supervisor: Dr. Hude Quan Thesis: Epidemiology and outcomes of primary biliary cirrhosis in the Calgary Health Region: A population-based study.

iv. Licensure Exams LMCC Part I − 1996

LMCC Part II − 1997

Certification Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) Specialty of Internal Medicine − 2000

Medical Licensure Alberta College of Physicians and Surgeons

License as a Specialist in Internal Medicine (License No. 013269)

III. AWARDS AND DISTINCITIONS

University of Calgary, Faculty of Medicine, Division of Gastroenterology

• 2014, GI Fellowship Resident Education Award. In recognition of excellence in research mentorship.





University of Calgary, Faculty of Medicine

• 2008, Cochrane Distinguished Achievement Award. In recognition of excellence in research.



Gastroenterology and Hepatology Awards Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: A Canadian population-based study from 1995 to 2004. Can J Gastroenterol 2008; 22(4):381-7. • 2009, Dr. ABR Thomson/Dr. CN Williams Award for best publication in the Canadian Journal

of Gastroenterology in 2008 (awarded by the Canadian Association of Gastroenterology and the Canadian Association for the Study of the Liver)

Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Ratziu V, Charlotte F, Bricaire F, Katlama C, Poynard T. Serum biochemical markers accurately predict liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients. • 2002, European Association for the Study of the Liver Traveling Bursary

Myers RP, Swain, MG, Lee SS. Reactivation of hepatitis Be antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. • 2001, Winner, ‘Consults in Gastroenterology’: Case Study Competition (Canadian Association

of Gastroenterology and AstraZeneca)

Myers RP, Chaudhary R, Fonseca K, Lee SS. Fatal hepatic decompensation in a patient with hepatitis B cirrhosis following famciclovir withdrawal. • 2000, Winner, ‘Consults in Gastroenterology’: Case Study Competition (Canadian Association

of Gastroenterology and AstraZeneca)

Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis: A vaccination in patients with chronic hepatitis C. • 2000, Best Oral Presentation, Canadian Digestive Diseases Week Fellows Course • 1999, American Digestive Health Foundation Student Abstract Prize • 1999, Physicians’ Services Incorporated (PSI) Foundation Resident Research Prize • 1999, American College of Physicians - Ontario Chapter Governor's Award, University of

Western Ontario Residents’ Research Day Myers RP, Gregor JC, McDonald JWD, Panaccione R, Feagan BG. Physicians’ perception of utility in Crohn’s disease. • 1998, Janssen-Ortho Gastroenterology Award, University of Western Ontario Residents’

Research Day

University of Western Ontario, Faculty of Medicine

• 1992, M. D.S. Health Group Limited Pathology Prize. Awarded to the medical student with the highest standing in Phase II Pathology.

• 1992, Dr. Marvin L. Kwitko Scholarship in Anatomy. Awarded to the medical student with the highest standing in Phase I Anatomy.

McMaster University, Faculty of Science

• 1991, Senate Scholarship. First-class standing in undergraduate science.

• 1990, Senate Scholarship. First-class standing in undergraduate science.

• 1989, Canada Scholarship. First-class standing in students entering undergraduate science.



IV. ACADEMIC APPOINTMENTS

Associate Professor of Medicine University of Calgary, Faculty of Medicine Department of Medicine Division of Gastroenterology April 1, 2010 Assistant Professor of Medicine University of Calgary, Faculty of Medicine

Department of Medicine Division of Gastroenterology June 1, 2004 − March 31, 2010

Clinical Scholar Division of Gastroenterology

Department of Medicine, Faculty of Medicine University of Calgary January 1, 2003 − May 31, 2004

V. EDUCATIONAL ACTIVITIES

i. Undergraduate

Lecturer Gastrointestinal Course – MDCH 408 University of Calgary School of Medicine

December 1, 2003 – present Responsible for providing lectures, small group precepting, and GI clinical correlation on a variety of liver and gastrointestinal problems.

ii. Postgraduate

Lecturer Administrative Data Analysis – MDCH 664 University of Calgary, Department of Community Health Sciences (March 2012) “U.S. Administrative Data”

Lecturer Fundamentals of Epidemiology - MDSC 647.01

University of Calgary, Department of Community Health Sciences (October 2004, 2007) “Evaluating a New Diagnostic Test”

Supervisor Masters Students Jack Pang (Sept 2012-September 2014)

David Sabapathy (September 2011-December 2013, supervisory committee) Natalie Molodecky (September 2010-June 2012, supervisory committee)

Hepatology Postdoctoral Research Fellow Dr. Abdel Aziz Shaheen (2006-2009)

Hepatology Fellowship Training Program

Dr. Stephen Congly (January 2011 – June 2012)



Supervisor (cont’d) Postdoctoral and Research Fellows

Dr. Matt Sadler (2012-2014) Dr. Erin Ross (2012 – 2014) Dr. Laura Stinton (2011 – 2014) Dr. Meredith Borman (2011 – 2014) Dr. Meena Mathivanan (2011 – 2014) Farah Ladak (2011 – 2012) Chris Schneider (2011 – 2012)

iii. Continuing Medical Education

• Annual CDDW/CASL conference. Montreal, QC. February 24-27, 2012

• Western IBD Symposium with Highlights in Hepatology. Banff, Alberta. November 25-27, 2011

• 2011 Annual Digestive Disease Week Conference. Chicago, Illinois. May 5-8, 2011

• Invited speaker at the 2011 GIRG Symposium in Banff, Alberta. March 18, 2011

• 2011 Annual CDDW conference in Vancouver, BC. February 26-March 1, 2011

• Autoimmune Liver Diseases. Canadian Liver Foundation Education Series. Calgary, Alberta, March 2009.

• The ABC’s of Hepatitis. Canadian Liver Foundation Education Series. Calgary, Alberta, March 2007, 2008.

• Management of Patients with Cirrhosis. Rural Physicians Education Program. University of Calgary, Calgary, Alberta, March 2007.

• 29th Family Practice Review and Update 2004, Calgary, November 2004: “Hepatitis C: An Update”



VI. ADMINISTRATIVE RESPONSIBILITIES

i. Departmental Acting Director Liver Unit at the University of Calgary (July 2011 – June 2012)

Director of Research GI Fellowship Program, University of Calgary (2009-2012)

Member GI Graduate Education Committee (2003-2005, 2009-2012)

ii. National

Chair Education Committee, Canadian Association for the Study of the Liver (2008-2012)

Member Education Committee, Canadian Association for the Study of the Liver (2005-2012)

Member National Education Advisory Committee, Canadian Liver Foundation (2007-present)

iii. Provincial

Member Expert Advisory Group on Hepatitis C Screening in Alberta,

Alberta Health Services (2014-present)

Member Expert Advisory Group on Use of Transient Elastography in Alberta, Alberta Health Services (2013-present)

iv. International

Consultant Consultant on collaborative health services research projects for

the Joint Liver Institute in Beijing China (June 2011 – present) VII. PROFESSIONAL ACTIVITIES

i. Membership in professional and learned societies Canadian Association for the Study of the Liver (CASL) American Association for the Study of Liver Disease (AASLD) European Association for the Study of the Liver (EASL) Canadian Association of Gastroenterology (CAG) Alberta Medical Association (AMA) Alberta Society of Gastroenterology (ASG) Calgary Regional Medical Staff Association University of Calgary Gastrointestinal Research Group (GIRG) University of Calgary Institute of Infection, Immunity and Inflammation (III)

ii. Professional service

Medical Director University of Calgary Viral Hepatitis Clinic Responsible for clinic operations and supervision of clinic staff (5 research nurses, 3 research assistants, 2 nurse clinicians, 3 clerks)



ii. Professional service (cont’d) Member University of Calgary Liver Unit

Responsible for providing Hepatology clinical services to the Calgary Health Region

Member Organizing Committee

2011 Canadian Consensus Conference on the Management of Viral Hepatitis, Canadian Association for the Study of the Liver

Member Writing Committee

2011 and 2004 Canadian Consensus Conference on the Management of Viral Hepatitis, Canadian Association for the Study of the Liver

Member Expert Committee 2007 Canadian Consensus Conference on the Management of Viral Hepatitis, Canadian Association for the Study of the Liver

2002 French Consensus Conference on the Management of Hepatitis C, Association Française pour l’Étude du Foie

Editorships Associate Editor

American Journal of Gastroenterology (2013-present) Editorial Board Hepatology (2012-present) Canadian Journal of Gastroenterology (2005-present) Annals of Hepatology (2008-present)

Grant Reviewer Health Professionals’ Fellowship Committee, CIHR (2010-present)

Physicians’ Services Inc. Foundation (2003, 2007, 2014) Saskatchewan Digestive Health Foundation (2003)

Canadian Liver Foundation (2005-present; Summer studentships and operating grants) Canadian Association for the Study of the Liver (2005-present; Hepatology Fellowship grants)

Abstract Reviewer American Gastroenterological Association Digestive Diseases

Week, Hepatobiliary Abstracts (2006, 2007)

Conference Chairs ‘’Evidence-Based Hepatology Practice’’. Oral abstract session at Digestive Diseases Week. New Orleans, LA, May 4, 2010.

“The Failing Liver: Managing the Patient with End-Stage Liver Disease”. Postgraduate Course of the 2009 Annual Meeting of the CAG and CASL; Banff, Alberta, Feb 27, 2009. Co-chair and organizer with Dr. Alaa Rostom.

“Clinical Hepatitis: Advances in the basis for and markers of progressive disease”. Oral abstract session at DDW. Washington, DC, May 22, 2007. Session Chair.

“HCV and Its Therapy” Symposium at the Annual Meeting of the Canadian Association for the Study of the Liver; Banff, Alberta, Feb 17, 2007. Co-chair and organizer with Dr. Jenny Heathcote.



VIII. RESEARCH SUPPORT

• Canadian Institutes of Health Research (CIHR) Team Grant Award July 1, 2014-June 30, 2019 Study: Brain Dysfunction in Chronic Inflammatory Disease: Reciprocal Effects of CNS and Periphery Crosstalk Role: Co-Applicant Support: $2,292,479

• Canadian Institutes of Health Research (CIHR) Catalyst Grant Award March 1, 2010-February 28, 2011 Study: National Trends in Hepatitis C-Related Hospitalizations, Liver Transplants, Mortality, and Utilization of Antiviral Therapies Role: Principal Applicant Support: $99,686

• Canadian Institutes of Health Research (CIHR) New Investigator Award July 1, 2008-June 30, 2013 Study: Noninvasive prediction of hepatic fibrosis using serum markers in patients with nonalcoholic fatty liver disease. Role: Principal Applicant Support: $300,000

• Alberta Heritage Foundation for Medical Research (AHFMR) Clinical Investigator Renewal July 1, 2008 – June 30, 2011 Study: Optimizing the management of patients with chronic liver disease. Role: Principal Applicant Support: $212,000

• MSI Foundation Operating Grant September 1, 2009-August 31, 2011 Study: Hospitalization for IBD: Risk factors, temporal trends, and health care utilization Role: Co-Applicant Support: $50,000

• Canadian Institutes of Health Research (CIHR) Operating Grant July 1, 2007-June 30, 2010 Study: Noninvasive prediction of hepatic fibrosis using serum markers in patients with nonalcoholic fatty liver disease. Role: Principal Applicant Support: $173,396

• Canadian Liver Foundation (CLF) September 1, 2007-August 31, 2009 Study: Noninvasive prediction of hepatic fibrosis using serum markers in patients with chronic hepatitis B. Role: Principal Applicant Support: $118,832

• Calgary Laboratory Services (CLS) September 1, 2007-August 31, 2009 Study: Noninvasive prediction of large esophageal varices in patients with cirrhosis using biochemical markers of fibrosis. Role: Principal Applicant Support: $7,851

• Alberta Heritage Foundation for Medical Research (AHFMR) Clinical Investigator July 1, 2005 – June 30, 2008 Study: Noninvasive prediction of hepatic fibrosis using serum biochemical markers in patients with chronic hepatitis C. Role: Principal Applicant Support: $255,000



• Alberta Heritage Foundation for Medical Research (AHFMR) Clinical Fellowship January 1, 2003 – June 30, 2004 (transferred from Paris, France) Department of Community Health Sciences, University of Calgary Supervisor: Dr. Hude Quan Master’s Thesis: Population-based study of the epidemiology of primary biliary cirrhosis in the Calgary Health Region. Role: Principal Applicant Support: $27,500

• Alberta Heritage Foundation for Medical Research (AHFMR) Clinical Fellowship July 1, 2002 – December 30, 2002 Groupe Hospitalier Pitié-Salpêtrière, Université de Paris VI, Paris, France Supervisor: Professor Thierry Poynard Projects included: Analysis of the operating characteristics of noninvasive markers of liver fibrosis in hepatitis C and hepatitis B, and antiviral therapy for HIV/HCV coinfected non-responders to interferon-based therapy. Role: Principal Applicant Support: $8,500

• Canadian Institutes of Health Research (CIHR) Fellowship (Ranked 1st out of 122 applicants) July 1, 2002 – June 30, 2003 Groupe Hospitalier Pitié-Salpêtrière, Université de Paris VI, Paris, France Supervisor: Professor Thierry Poynard Projects included: Noninvasive markers of liver fibrosis in hepatitis C with and without HIV coinfection; predictors of hepatitis C-related liver fibrosis progression, and antiviral therapy for hepatitis C infection. Role: Principal Applicant Support: $55,000

• Canadian Association for the Study of the Liver (CASL) / Axcan Pharma Hepatology Research Fellowship, 2002 (declined)

• Canadian Association for the Study of the Liver (CASL) / Schering Canada / Dr. V. Feinman Hepatology Research Fellowship July 1, 2001 – June 30, 2002 Groupe Hospitalier Pitié-Salpêtrière, Université de Paris VI, Paris, France Supervisor: Professor Thierry Poynard Project: Noninvasive prediction of hepatic fibrosis in chronic hepatitis C using a predictive index and serum markers of hepatic fibrosis. Role: Principal Applicant Support: $55,000

• Detweiler Traveling Fellowship, Royal College of Physicians and Surgeons of Canada July 1, 2001 – June 30, 2002 Groupe Hospitalier Pitié-Salpêtrière, Université de Paris VI, Paris, France Supervisor: Professor Thierry Poynard Project: Noninvasive prediction of hepatic fibrosis in chronic hepatitis C using a predictive index and serum markers of hepatic fibrosis. Role: Principal Applicant Support: $7,000



National Principal Investigator on the following Industry-sponsored clinical trials: 1) Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients. Sponsored by Echosens.

Enrollment completed and 2 manuscripts published.

2) National Outcomes Study for Treatment of Hepatitis C with PEGASYS RBV (peginterferon alfa-2a and ribavirin). The APPROACH Study. Sponsored by Roche Pharmaceuticals. Enrollment completed and manuscript published.

3) The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication

(IMPROVE) Trial: Randomized, Open-label, Multicentre, Study Evaluating the Efficacy and Safety of 48 or 72 weeks of Treatment with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) Combination Therapy in Non-genotype 2/3 Patients with Chronic Hepatitis C Virus Infection who have Undetectable HCV-RNA or a ≥2-log10 drop at Week 12. The IMPROVE Study. Sponsored by Roche Pharmaceuticals. Enrollment completed and manuscript published.

Principal Investigator on the following Investigator-initiated clinical trials: 1) Rituximab in primary biliary cirrhosis refractory to ursodeoxycholic acid. Supported by

Genentech, Inc. ($55,000). Enrollment completed and manuscript published. Preliminary data presented in February 2007 at the B-Cell Summit (Newport Beach, California) and May 2007 (Clues in the Pathogenesis of Autoimmune Biliary Diseases: PBC and PSC, Toronto, Ontario).

2) FibroScan for the prediction of fibrosis in patients with chronic hepatitis B and C and nonalcoholic

fatty liver disease. National principal investigator of 5 center Canadian study (the Canadian Liver Fibrosis Study Group). Enrollment completed and 3 manuscripts published.

Co-Investigator on the following Investigator-initiated clinical trials: 1) Rituximab for the treatment of patients with refractory autoimmune hepatitis. Supported by

Genentech, Inc. ($40,492). Enrollment completed and manuscript published. 2) Neoral versus Tacrolimus for the prevention of hepatitis C recurrence post liver transplantation.

Supported by Novartis ($424,000). Enrollment completed.



IX. INVITED ADDRESSES Ultrasound Elastography for Assessment of Diffuse Liver Disease • Society of Radiologists in Ultrasound (Denver, CO). Oct 21-22, 2014. Noninvasive Assessment of Liver Fibrosis. • Translational Approaches to Inflammatory Liver Injury and Repair (TAILOR) Meeting (Banff,

AB). Sept. 19, 2014. The Burden of Chronic Hepatitis C Virus Infection in Canada. • GI and Liver Association of the Americas (GALA) (Montreal, PQ). Sept. 6, 2014. Does One Size Fit All? How Do We Offer the Highest Probability of Virologic Cure in HCV? • GI and Liver Association of the Americas (GALA) (Montreal, PQ). Sept. 6, 2014. Assessment of Hepatic Parenchyma: Hepatic Fibrosis. • AASLD Emerging Trends Conference, Emerging Trends in Liver Imaging. Emory Conference

Center Hotel in Atlanta, Georgia. September 8-9, 2012. Is staging hepatic fibrosis for chronic hepatitis C in 2012 required? • Annual Digestive Disease Week Conference. San Diego, California. May 18-23, 2012

2012 CASL Guidelines on the Management of Chronic Hepatitis C. • Clinical Symposium on HCV Management (Toronto, Ontario). May 12, 2012 2012 CASL Guidelines for the Management of Hepatitis C. • Red Deer Regional Hospital for HCV treaters and nurses. May 3, 2012 New HCV Treatment Modalities: The New Era; Phase III BOC, Telaprevir Trial. • HepCBC Meeting. Victoria, British Columbia. March 2, 2012 Discuss announcement by US CDC (and a few weeks earlier by AASLD researchers) that more people in the USA have died of HCV than HIV since 2007. • Radio Interview for HepCBC Hepatitis C Education and Prevention Society. February 29, 2012 M11-652 Hepatitis C study investigator meeting. • Panel member for Hepatitis C Investigator meeting. Los Angeles, CA. October 14, 2011 Lectures on : 1) The management of patients with cirrhosis undergoing surgery

2) Management of esophageal varices. • GI Forum held in Vancouver, British Columbia. October 13, 2011 Expert opinion and guidance on clinical development plan for Simeprevir/TMC 435. • National Simeprevir Advisory Board Meeting. Toronto, Ontario. September 16, 2011 Canadian Association for the Study of the Liver. • Governing Board Meeting. February 26, 2011

Topic: Assessing the severity of Liver Disease focusing on Biopsy and Fibroscan. • Canadian Liver Foundation Living with Liver Disease session October 11, 2011 Administrative Databases in Liver-Related Research • Youan Hospital, Beijing, China, November 23, 2010 • China-Japan Friendship Hospital, November 24, 2010



Contraindications to Liver Biopsy • Digestive Diseases Week, New Orleans, Louisiana, May 4, 2010. Transient Elastography (FibroScan): Promises and Pitfalls • The Liver and Intestinal Research Centre, Vancouver, British Columbia, March 25, 2010

HCV in 2010: Should I Treat or Should I Wait? • Calgary Urban Project Society (CUPS) Health Centre, Calgary, Alberta, March 18, 2010

Transient Elastography (FibroScan): Promises and Pitfalls (Breakfast session) • Canadian Association for the Study of the Liver/Canadian Digestive Disease Week 2010.

Toronto, Ontario, March 9, 2010.

The Burden of HCV in Canada: Implications for Liver Transplantation • 5th annual Canadian Liver Transplant Forum, Toronto, Ontario, February 26, 2010. Noninvasive assessment of liver fibrosis: The end of biopsy? • Kelowna Digestive Diseases Weekend. Kelowna, British Columbia, May 1-3, 2009. Primary biliary cirrhosis: An update. • Kelowna Digestive Diseases Weekend. Kelowna, British Columbia, May 1-3, 2009. Difficult cases of hepatitis C. • Kelowna Digestive Diseases Weekend. Kelowna, British Columbia, May 1-3, 2009. Practical applications of transient elastography (FibroScan) for the assessment of liver fibrosis. • Hôpital Maisonneuve-Rosemont, Montreal, QC, March 18, 2009. Transient elastography (FibroScan) for the assessment of liver fibrosis: A review. • Hôpital Maisonneuve-Rosemont. Montreal, QC, March 17, 2009. Noninvasive markers of liver fibrosis (Meet the Experts session). • Canadian Association for the Study of the Liver/Canadian Digestive Disease Week 2007.

Banff, Alberta, March 1, 2009. Noninvasive markers of liver fibrosis (Early Morning Workshop). • 2008 Annual Meeting of the American Association for the Study of the Liver. San Francisco,

California, November 3, 2008.

New diagnostic tools in assessment of liver injury fibrosis, steatosis and function. • Postgraduate Course of the 2008 Annual Meeting of the American Association for the Study of

the Liver. San Francisco, California, October 31, 2008. Noninvasive markers of nonalcoholic fatty liver disease. • Nonalcoholic Fatty Liver Disease Symposium. Medica Sur Clinic Foundation. Mexico City,

Mexico, October 3, 2008. Liver biopsy and noninvasive options. • 2008 Annual Meeting of the Mexican Association of Hepatology. San Cristobal de las Casas,

Chiappas, Mexico, June 28, 2008.



Noninvasive markers of liver fibrosis (Early Morning Workshop). • 2008 Annual Meeting of the Mexican Association of Hepatology. San Cristobal de las Casas,

Chiappas, Mexico, June 28, 2008. What’s new in primary biliary cirrhosis? • 2008 Annual Meeting of the Mexican Association of Hepatology. San Cristobal de las Casas,

Chiappas, Mexico, June 26, 2008. Noninvasive markers of nonalcoholic fatty liver disease. • 2008 Annual Meeting of the Mexican Association of Hepatology. San Cristobal de las Casas,

Chiappas, Mexico, June 25, 2008. Rituximab for the treatment of PBC – What does its effect tell us? • Clues in the Pathogenesis of Autoimmune Biliary Diseases: PBC and PSC. Toronto, Ontario,

May 17, 2007. Noninvasive Markers of Liver Fibrosis: The time is now, the place is here! • University of Toronto Hepatology Update 2007. Toronto, Ontario, March 30, 2007. Rituximab in primary biliary cirrhosis refractory to ursodeoxycholic acid: A preliminary report. • The B-Cell Summit. Newport Beach, California. February 21-23, 2007. Noninvasive Markers of Liver Fibrosis • Canadian Association for the Study of the Liver/Canadian Digestive Disease Week 2007.

Banff, Alberta, February 17-18, 2007. Noninvasive Assessment of Liver Fibrosis: Throw Away that Biopsy Needle! • Gastrointestinal Research Group Retreat. University of Calgary. Kananaskis, Alberta, January

28, 2007. Altering Treatment Duration in Patients with Genotype 1 Hepatitis C Virus Infection • Canadian Consensus Conference for the Management of Viral Hepatitis. Canadian

Association for the Study of the Liver (CASL). Toronto, Ontario, January 4, 2007. Antivirals for Liver Disease. • Canadian Digestive Diseases Week Postgraduate Course, Annual Meeting of the Canadian

Association of Gastroenterology. Banff, Alberta, February 25, 2006. Treatment of Hepatitis B: Interferons and Nucleoside Analogs. • 1st Annual Meeting of the Canadian Association for the Study of the Liver. Banff, Alberta,

March 2005. The Impact of Site of Attachment and PEG Size on Activity of Peginterferons. • 1st Annual Meeting of the Canadian Association for the Study of the Liver. March 2005. Hepatitis B: An Update and Recommendations for Healthy Living. • Calgary Health Region Communicable Diseases Unit, Calgary, Alberta, December 1, 2005. Hepatitis C: An Update • University of Calgary Family Practice Update, Calgary, Alberta, November 15, 2004.

Approach to Severe Acute Hepatitis • 4th Annual GI Emergencies Conference, Banff, Alberta, October 23, 2004.



Biochemical Markers of Liver Fibrosis: Current Opinions • Prognostic Markers of Liver Disease Symposium. American Gastroenterological Association

(AGA) Digestive Diseases Week. New Orleans, Louisiana, May 18, 2004. Making Sense of Small-Duct Diseases • Update on Liver and Inflammatory Bowel Diseases (ULIBD). Cancun, Mexico, April 1, 2004. Consequences of Cirrhosis: A Healthcare Adaptation • University of Calgary, 14th Annual Gastrointestinal Research Group (GIRG) Retreat. Banff,

Alberta, March 27, 2004.

Multiple Hepatotrophic Infections • American Society of Microbiology. Lake Tahoe, Nevada, October 20, 2003. Viral Hepatitis: A Review • Alberta College of Medical Laboratory Technicians. Canmore, Alberta, September 18, 2003. Hepatitis B in the 21st Century: Beyond Interferon and Lamivudine • Kelowna Digestive Diseases Weekend. Kelowna, British Columbia, September 12-14, 2003. Extrahepatic Manifestations of Chronic Hepatitis C • Kelowna Digestive Diseases Weekend. Kelowna, British Columbia, September 12-14, 2003. Interferon for acute HCV and interferon nonresponding and relapsing chronic HCV: Two Cochrane Reviews • The Cochrane Hepato-Biliary Group. American Association for the Study of Liver Diseases.

Boston, Massachussetts, November 4, 2002. Screening for hepatocellular carcinoma: What should we do? Is it cost-effective? • Alberta Society of Gastroenterology. Kananaskis, Alberta, September 14, 2002. L’hépatite aiguë C: Recommandations de traitement. • Conférence de Consensus: Traitement de l’Hépatite C. L’Assocation Française pour l’Ėtude

du Foie (AFEF). Paris, France, February 27, 2002. Hepatitis C in HIV-coinfected patients: An emerging opportunistic pathogen. • Gastrointestinal Research Group Retreat. University of Calgary. Banff, Alberta, January 25,

2002. Serum markers of fibrosis in chronic hepatitis C: Towards a reduction in liver biopsies. • Liver Club Meeting. Canadian Association for the Study of the Liver. Dallas, Texas, November

9, 2001.



X. PUBLICATIONS / PRESENTATIONS

i. Peer Reviewed Manuscripts (trainees underlined) Published 1. Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D,

Qian DC, et al. Myers RP (collaborator). Nat Commun. 2015 Sep 22;6:8019.

2. Pang JX, Ross E, Borman MA, Zimmer S, Kaplan GG, Heitman SJ, Swain MG, Burak KW, Quan H, Myers RP. Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data. BMC Gastroenterol. 2015 Sep 11;15:116.

3. Samadi Kochaksaraei G, Castillo E, Osman M, Simmonds K, Scott AN, Oshiomogho JI, Lee SS, Myers RP, Martin SR, Coffin CS. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat. 2015 Jul 20. [Epub ahead of print].

4. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JX, Beaumont C, Esfandiari N, Myers RP. Inclusion of Sarcopenia within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients with Cirrhosis. Clin Transl Gastroenterol. 2015 Jul 16;6:e102.

5. Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology. 2015 Sep;276(3):845-61.

6. Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, Bain VG, Kneteman NM, Hilsden RJ. Validation, current use and future directions of the Model for End-stage Liver Disease for liver transplant allocation in Canada. Can J Gastroenterol Hepatol. 2015 Jun 15. [Epub ahead of print]

7. Sadler MD, Crotty P, Fatovich L, Wilson S, Rabin HR, Myers RP. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis. Can J Gastroenterol Hepatol. 2015 Apr;29(3):139-44.

8. Pang JX, Ross E, Borman MA, Zimmer S, Kaplan GG, Heitman SJ, Swain MG, Burak K, Quan H, Myers RP. Risk factors for mortality in patients with alcoholic hepatitis and assessment of prognostic models: A population-based study. Can J Gastroenterol Hepatol. 2015 Apr;29(3):131-8.

9. Myers RP, Crotty P, Town S, English J, Fonseca K, Tellier R, Swain MG, McGregor SE, Heitman SJ, Hilsden RJ. Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. CMAJ Open. 2015 Jan 13;3(1):E62-7.

10. Myers RP, Shaw H, Burak KW. Re: RP Myers, H Shah, KW Burak, et al. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29(1):19-34. Can J Gastroenterol Hepatol. 2015 Mar;29(2):68.

http://www.ncbi.nlm.nih.gov/pubmed/26192022











11. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Erratum in: Can J Gastroenterol Hepatol. 2015 Mar;29(2):68.

12. Sadler MD, Ravindran NC, Hubbard J, Myers RP, Ghosh S, Beck PL, Dixon E, Ball C, Prusinkiewicz C, Heitman SJ, Kaplan GG. Predictors of mortality among patients undergoing colectomy for ischemic colitis: A population-based United States study. Can J Gastroenterol Hepatol. 2014 Dec;28(11):600-4.

13. Quan S, Frolkis A, Milne K, Molodecky N, Yang H, Dixon E, Ball CG, Myers RP, Ghosh S, Hilsden R, van Zanten SV, Kaplan GG. Upper-gastrointestinal bleeding secondary to peptic ulcer disease: incidence and outcomes. World J Gastroenterol. 2014 Dec 14;20(46):17568-77.

14. Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014 Dec;40(11-12):1262-9

15. Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A, Estes C, Razavi H, Sherman M. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014 May;28(5):243-50.

16. Pang JX, Zimmer S, Niu S, Crotty P, Tracey J, Pradhan F, Shaheen AA, Coffin CS, Heitman SJ, Kaplan GG, Swain MG, Myers RP. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One. 2014 Apr 22;9(4):e95776.

17. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014 May;21 Suppl 1:60-89.

18. Razavi H, Waked I, Sarrazin C, Myers RP, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014 May;21 Suppl 1:34-59.

19. Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F,

Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014 May;21 Suppl 1:5-33.














20. Pang JX, Pradhan F, Zimmer S, Niu S, Crotty P, Tracey J, Schneider C, Heitman SJ,

Kaplan GG, Swain MG, Myers RP. The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations. Can J Gastroenterol Hepatol. 2014 Jan;28(1):23-30.

21. Sebastiani G, Ghali P, Wong P, Klein MB, Deschenes M, Myers RP. Physicians' practices

for diagnosing liver fibrosis in chronic liver diseases: A nationwide, Canadian survey. Can J Gastroenterol. 2014;28(1):23-30.

22. Myers RP, Tandon P, Ney M, Meeberg G, Faris P, Shaheen AA, Aspinall AI, Burak KW.

Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. Liver Int. 2014 Sep;34(8):1176-83.

23. Grebely J, Bilodeau M, Feld JJ, Bruneau J, Fischer B, Raven JF, Roberts E, Choucha N,

Myers RP, Sagan SM, Wilson JA, Bialystok F, Tyrrell DL, Houghton M, Krajden M; National CIHR Research Training Program in Hepatitis C. The Second Canadian Symposium on hepatitis C virus: a call to action. The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol. 2013;27(11):627-32.

24. Abdo AA, Bzeizi KI, Babatin MA, Alsohaibani F, Almana H, Alsaad KO, Alghamdi H, Al-

Hamoudi W, Alswat K, Alfaleh FZ, Myers RP, Sanai FM. Predictors of Significant Fibrosis in Chronic Hepatitis B Patients With Low Viremia. J Clin Gastroenterol. 2014 Jul;48(6):e50-6.

25. James PD, Kaplan GG, Myers RP, Hubbard J, Shaheen AA, Tinmouth J, Yong E, Love J,

Heitman SJ. Decreasing mortality from acute biliary diseases that require endoscopic retrograde cholangiopancreatography: A nationwide cohort study. Clin Gastroenterol Hepatol. 2014 Jul;12(7):1151-1159.

26. Munene G, Parker RD, Shaheen AA, Myers RP, Quan ML, Ball CG, Dixon E. Disparities in

the surgical treatment of colorectal liver metastases. J Natl Med Assoc. 2013;105(2):128-37.

27. Congly SE, Wong P, Al-Busafi SA, Doucette K, Fung SK, Ghali P, Fonseca K, Myers RP,

Osiowy C, Coffin CS. Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres. Liver Int. 2013 Oct;33(9):1363-9.

28. Kaplan GG, Tanyingoh D, Dixon E, Johnson M, Wheeler AJ, Myers RP, Bertazzon S,

Saini V, Madsen K, Ghosh S, Villeneuve PJ. Ambient ozone concentrations and the risk of perforated and nonperforated appendicitis: A multicity case-crossover study. Environ Health Perspect. 2013;121(8):939-43.

29. Sanai FM, Babatin MA, Bzeizi KI, Alsuhaibani F, Al-Hamoudi W, Alsaad KS, Almana H,

Handoo FA, Al-Ashgar H, Alghamdi H, Ibrahim A, Aljumah A, Alalwan A, Altraif IH, Al-Hussaini H, Myers RP, Abdo AA. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen-negative patients with chronic hepatitis. Clin Gastroenterol Hepatol. 2013;11(11):1493-1499.e2.

30. Borman MA, Ladak F, Crotty P, Pollett A, Kirsch R, Pomier-Layrargues, Beaton M, Duarte-

Rojo A, Elkashab M, Myers RP. The fatty liver index has limited utility for the detection and quantification of hepatic steatosis in obese patients. Hepatol Int. 2013 Jun;7(2):592-9.

















31. Burak KW, Swain MG, Santodomino-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, Coffin CS, Myers RP. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27(5):273-80.

32. Coffin CS, Osiowy C, Myers RP, Gill MJ. Virology and clinical sequelae of long-term

antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. J Clin Virol. 2013;57(2):103-8.

33. Myers RP, Shaheen AA, Faris P, Aspinall AI, Burak KW. Revision of MELD to include

serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS One. 2013;8(1):e51926.

34. Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW. B-cell depletion with rituximab in

patients with primary biliary cirrhosis refractory to ursodeoxycholic Acid. Am J Gastroenterol. 2013;108(6):933-41.

35. Pradhan F, Ladak F, Tracey J, Crotty P, Myers RP. Feasibility and reliability of the

FibroScan S2 (pediatric) probe compared with the M probe for liver stiffness measurement in small adults with chronic liver disease. Ann Hepatol. 2013;12(1):100-7.

36. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R,

Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(7):868-875.

37. Steadman R, Myers RP, Leggett L, Lorenzetti D, Noseworthy T, Rose S, Sutherland L,

Clement F. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-58.

38. Stinton LM, Myers RP, Coffin CS, Fritzler MJ. Clinical associations and potential novel

antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterol. 2013;13:50.

39. Grendar J, Shaheen AA, Myers RP, Parker R, Vollmer CM Jr, Ball CG, Quan ML, Kaplan

GG, Al-Manasra T, Dixon E. Predicting in-hospital mortality in patients undergoing complex gastrointestinal surgery: Determining the optimal risk adjustment method. Arch Surg 2012;147(2):126-35.

40. Hirschfield GM, Xie G, Lu E, Sun Y, Juran BD, Chellappa V, Coltescu C, Mason AL,

Milkiewicz P, Myers RP, et al. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun. 2012;13(4):328-35.

41. Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun

Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Heathcote EJ, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC Jr, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, Deandrade M, Amos CI; The Italian PBC Genetics Study Group, Lazaridis KN, Seldin MF, Siminovitch KA. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet. 2012;21(23):5209-21.





42. Lee SS, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, Hilzenrat N, Balshaw R, Usaty C, Myers RP. Randomized clinical trial: The efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. Aliment Pharmacol Ther. 2012;35(1):37-47.

43. Ma C, Crespin C, Proulx MC, Desilva S, Hubbard J, Prusinkiewicz M, Nguyen GC,

Panaccione R, Ghosh S, Myers RP, Quan H, Kaplan GG. Postoperative complications following colectomy for ulcerative colitis: A validation study. BMC Gastroenterol. 2012 Apr 27;12:39.

44. Myers RP. Is the M probe really necessary to measure liver stiffness by FibroScan?

Hepatology. 2012;55(6):2044. 45. Myers RP, Hubbard JN, Shaheen AA, Dixon E, Kaplan GG. Hospital performance reports

based on severity adjusted mortality rates in patients with cirrhosis depend on the method of risk adjustment. Ann Hepatol. 2012;11(4):526-35.

46. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M,

Levstik M, Crotty P, Landau M, Miette V, Sasso M, Elkashab M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55(1):199-208.

47. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Beaton M, Levstik M, Duarte-Rojo A,

Wong D, Crotty P, Elkashab M. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol. 2012;56(3):564-70.

48. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of

hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol. 2012;26(6):359-75.

49. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, Duarte-Rojo A,

Wong D, Crotty P, Elkashab M. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32(6):902-10.

50. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, Esfandiari N, Baracos V,

Montano-Loza AJ, Myers RP. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012;18(10):1209-16.

51. Burak KW, Coffin CS, Myers RP. Hepatitis B education: A failing grade (Editorial). Can J

Gastroenterol. 2011;25(3):125-6. 52. Congly S, Shaheen AA, Meddings L, Kaplan GG, Myers RP. Amoebic liver abscess in the

United States: A population-based study of incidence, temporal trends, and mortality. Liver Int. 2011;31(8):1191-8.

53. Drolet S, Maclean AR, Myers RP, Shaheen AA, Dixon E, Buie WD. Elective resection of

colon cancer by high-volume surgeons is associated with decreased morbidity and mortality. J GI Surg. 2011;15(4):541-50.

54. Guha IN, Myers RP, Patel K, Talwalkar JA.* Biomarkers of liver fibrosis: What lies beneath

the receiver operator characteristic curve? Hepatology. 2011;54(4):1454-62. *Equal contribution from all authors.



55. Kaplan GG, Hubbard J, Panaccione R, Shaheen AA, Quan H, Nguyen GC, Dixon E,

Ghosh S, Myers RP. The risk of comorbidities on postoperative outcomes in inflammatory bowel disease patients. Arch Surg. 2011;146(8):959-64.

56. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY,

Myers RP, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized open-label study. Hepatology. 2011;54(1):91-100.

57. Molodecky N, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. The

incidence of primary sclerosing cholangitis: A systematic review and meta-analysis. Hepatology. 2011;53(5):1590-9.

58. Molodecky N, Myers RP, Barkema HW, Quan H, Kaplan GG. Validity of administrative

data for the diagnosis of primary sclerosing cholangitis (PSC): A population-based study. Liver Int. 2011;31(5):712-20.

59. Montano-Loza AJ, Myers RP, Mason AL. Lessons learned from liver transplantation with

the Canadian First Nations (Editorial). Can J Gastroenterol. 2011;25(6):305-6. 60. Myers RP, Cooper C, Sherman M, Lalonde R, Witt-Sullivan H, Elkashab M, Harris P,

Balshaw R, Usaty C, Marotta PJ. Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada). Can J Gastroenterol. 2011;25(9):503-10.

61. Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G,

Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol. 2011;18(5):228-40.

62. Stinton LM, Swain M, Myers RP, Shaheen AA, Fritzler MJ. Autoantibodies to GW bodies

and other autoantigens in primary biliary cirrhosis. Clin Exp Immunol. 2011;163(2):147-56. 63. Coffin CS, Shaheen AA, Burak KW, Myers RP. Pregnancy outcomes among liver

transplant recipients in the United States: A nationwide case-control analysis. Liver Transpl. 2010;16(1):56-63.

64. Drolet S, Maclean AR, Myers RP, Shaheen AA, Dixon E, Donald Buie W. Morbidity and

mortality following colorectal surgery in patients with end-stage renal failure: a population-based study. Dis Colon Rectum. 2010;53(11):1508-16.

65. Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y, Chen W, Juran BD, Coltescu C,

Mason AL, Milkiewicz P, Myers RP, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):655-7.

66. Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, Podda M, Xu C, Xie G, Macciardi F,

Selmi C, Lupoli S, Shigeta R, Ransom M, Lleo A, Lee AT, Mason AL, Myers RP, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis Nat Genet. 2010;42(8):658-60.

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lu%20Y%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chen%20W%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Juran%20BD%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Coltescu%20C%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mason%20AL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Milkiewicz%20P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Myers%20RP%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Invernizzi%20P%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kosoy%20R%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bianchi%20I%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Podda%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xu%20C%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xie%20G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Macciardi%20F%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Selmi%20C%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lupoli%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shigeta%20R%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ransom%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lleo%20A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lee%20AT%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mason%20AL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Myers%20RP%22%5BAuthor%5D



67. Meddings L, Myers RP, Hubbard JN, Shaheen AA, Laupland K, Dixon E, Coffin C, Kaplan GG. A population-based study of pyogenic liver abscesses in the U.S.: Incidence, mortality, and temporal trends. Am J Gastroenterol. 2010;105(1):117-124.

68. Myers RP, Crotty P, Pomier-Layrargues G, Ma M, Urbanski SJ, Elkashab M. Prevalence,

risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. Liver Int. 2010;30(10):1471-80.

69. Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G. Transient elastography for

the noninvasive assessment of liver fibrosis: A multicentre Canadian study. Can J Gastroenterol. 2010;24(11):661-70.

70. Myers RP, Lee SS. Pay now or pay (more) later: Tracking the costs of hepatitis C infection

(Editorial). Can J Gastroenterol. 2010;24(12):715-6. 71. Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and

outcomes on the liver transplant waiting list: Assessment of revised MELD including estimated glomerular filtration rate. J Hepatol. 2010;54(3):462-70.

72. Myers RP, Shaheen AA, Wan AF, Swain MG, Hilsden RJ, Sutherland L, Quan H.

Validation of coding algorithms for the identification of patients with primary biliary cirrhosis using administrative data. Can J Gastroenterol. 2010;24(3):175-182.

73. Stinton LM, Myers RP, Shaffer E. Epidemiology of Gallstones. Gastroenterol Clin N Am.

2010;39(2):157-69, vii. 74. Hirschfield G, Liu X, Xu C, Lu Y, Gu X, Walker E, Jing K, Juran B, Mason A, Myers RP, et

al. Primary biliary cirrhosis: Association with HLA, IL12A, and IL12RB2. New England Journal of Medicine. 2009;360(24):2544-55.

75. Kaplan GG, Panaccione R, Hubbard JN, Nguyen GC, Shaheen AA, Ma C, Devlin SM,

Leung Y, Myers RP. IBD patients who leave against medical advice: Predictors and temporal trends. Inflamm Bowel Dis. 2009;15(6):845-51.

76. Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann Hepatol

2009;8(1): Supplement:S25-33. 77. Myers RP, Kaplan GG, Shaheen AA. The effect of weekend versus weekday admission

and outcomes of esophageal variceal hemorrhage. Can J Gastroenterol. 2009;23(7):495-501.

78. Myers RP, Hubbard JN, Shaheen AA, Kaplan GG. Predicting in-hospital mortality in

patients with cirrhosis: Results differ across risk-adjustment methods. Hepatology. 2009;49(2):568-77.

79. Myers RP, Shaheen AA, Hubbard JN, Kaplan GG. Characteristics of patients with cirrhosis

who are discharged from hospital against medical advice. Clin Gastroenterol Hepatol. 2009;7(7):786-92.

80. Myers RP, Shaheen AA, Fong, A, Burak, KW, Wan AF, Swain MG, Hilsden RJ, Sutherland

L, Quan H. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study. Hepatology. 2009;50(6):1884-1892.



81. Myers RP, Shaheen AA. Hepatitis C, alcohol abuse, and unintentional overdoses are risk factors for acetaminophen-related hepatotoxicity. Hepatology. 2009;49(4):1399-1400.

82. Shaheen AA, Hubbard JN, Kaplan GG, Myers RP. Morbidity and mortality following

coronary artery bypass graft (CABG) surgery in patients with cirrhosis: A population-based study. Liver Int. 2009;29(8):1141-51.

83. Shaheen AA, Myers RP. The outcomes of pregnancy in patients with cirrhosis: A

population-based study. Liver Int. 2009 30(2):275-83. 84. McColl RJ, You X, Ghali WA, Kaplan GG, Myers RP, Dixon E. Recent trends of hepatic

resection in Canada: 1995-2004. J Gastrointest Surg. 2008;12(11):1839-46 85. Myers RP. Noninvasive markers of liver fibrosis: Playing the probabilities (Editorial). Liver

Int. 2008;28(10):1328-31. 86. Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: A

Canadian population-based study from 1995 to 2004. Can J Gastroenterol. 2008; 22(4):381-7.

87. Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of

percutaneous liver biopsy: A population-based study including 4,275 biopsies. Liver Int. 2008;28(5):705-12.

88. Myers RP, Papay K, Shaheen AA, Kaplan GG. The relationship between hospital volume

and outcomes of esophageal variceal bleeding in the United States. Clin Gastro Hepatol. 2008;6(7):789-98.

89. Myers RP, Shaheen AA, Li B, Dean S, Quan H. The impact of liver disease, alcohol

abuse, and unintentional ingestions on the outcome of acetaminophen overdose. Clin Gastro Hepatol. 2008;6(8):918-25.

90. Myers RP, Shaheen AA. FibroTest has better diagnostic and prognostic values than APRI

in patients with chronic hepatitis C. Hepatology. 2008;47(1):354-6. 91. Shaheen AA, Hubbard JN, Kaplan GG, Myers RP. Weekend versus weekday admission

and mortality from gastrointestinal hemorrhage due to peptic ulcer disease. Clin Gastro Hepatol. 2008;7(3):303-10.

92. Shaheen AA, Myers RP.* Systematic review and meta-analysis of the diagnostic accuracy

of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clinical Trials 2008;9(1):43-51. (* Both authors contributed equally to this work).

93. Alqahtani S, Federico P, Myers RP. A case of hyperammonemic encephalopathy: Look

beyond the liver. CMAJ. 2007;177(6):568-9. 94. Chan HYL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, et

al. Antiviral efficacy of telbivudine vs adefovir and switching from adefovir to telbivudine in HBeAg-positive chronic hepatitis B: A randomized, controlled trial. Ann Intern Med. 2007;147(11):745-54.

95. Kaplan GG, Heitman SJ, Hilsden RJ, Urbanski S, Myers RP, et al. Population-based

analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis. 2007;13(11):1401-7.



96. Myers RP. Racial disparities in the management of hospitalized patients with cirrhosis and

portal hypertension. Hepatology. 2007;47(1):358-60. 97. Myers RP, Messous D, Poynard T, Imbert-Bismut F. Association between serum leptin,

metabolic factors and liver histological lesions in patients with chronic hepatitis C. Can J Gastro. 2007;21(5):289-94.

98. Myers RP, Leung Y, Li B, Shaheen AA. Validation of ICD-9-CM/ICD-10 coding algorithms

for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data. BMC Health Serv Res. 2007 Oct 2;7(1):159.

99. Myers RP, Li B, Fong A, Shaheen AA, Quan H. Hospitalizations for acetaminophen

overdose: A Canadian population-based study from 1995 to 2004. BMC Public Health. 2007;7:143.

100. Myers RP, Li B, Shaheen AM. Emergency department visits for acetaminophen overdose:

A Canadian population-based epidemiologic study (1994-2002). Can J Emerg Med. 2007;9(4):267-74.

101. Myers RP, Shaheen AA, Lee SS. Impact of pharmaceutical industry versus university

sponsorhship on survey response: A randomized trial among Canadian hepatitis C care providers. Can J Gastro. 2007;21(3):169-75.

102. Robbins S, Shaheen AA, Myers RP. Immunologic complications of the hepatitis C virus.

Curr Hep Reports. 2007;6(4):183-44. 103. Shaheen AA, Myers RP.* Diagnostic accuracy of the APRI for the prediction of hepatitis C-

related fibrosis: A systematic review. Hepatology. 2007;46(3):912-21. (* Both authors contributed equally to this work).

104. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis

C-related fibrosis: A systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102(11):589-600.

105. Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable

pancreatic cancer: A systematic review. Am J Gastroenterol. 2007;102(2):430–8. 106. Leung Y, Urbanski SJ, Schindel L, Myers RP. Ischemic colitis during peginterferon-alfa and

ribavirin therapy for chronic hepatitis C. Can J Gastro. 2006;20(10):661-3. 107. Yan B, Leung Y, Urbanski SJ, Myers RP. Rofecoxib-induced hepatotoxicity: A forgotten

complication of the coxibs. Can J Gastroenterol. 2006;20(5):351-5. 108. Cacoub P, Goderel I, Morlat P, Sene D, Myers RP, Alric L, et al. Management of chronic

hepatitis C in French departments of internal medicine and infectious diseases. Ther GERMIVIC Group. Epidemiol Infect. 2005;133(2):305-14.

109. Mayer K, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: A systematic review.

J Viral Hepat. 2005;12(6):559-67. 110. Di Martino V, Lebray P, Myers RP, Moussali J, Regimbeau C, Buffet C, Poynard T. Liver

fibrosis progression in hepatitis C virus-infected women: long-term benefit of estrogen exposure. Hepatology. 2004;40(6):1426-33.



111. Imbert-Bismut F, Messous D, Thabut D, Thibault V, Myers RP, et al. Intra-laboratory

analytical variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) and reference ranges in healthy blood donors. Clin Chem Lab Med. 2004;43(3):323-33.

112. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Peginterferon-α2b

and ribavirin in HIV/HCV-co-infected nonresponders and relapsers to interferon-based therapy. AIDS. 2004;18(1):75-9.

113. Myers RP. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization

(Correspondence). Radiology. 2004;230(1):300-2. 114. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, et al. Overview of the

diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV-Fibrosure) and histological activity (ActiTest) in patients with chronic hepatitis C. Comparative Hepatology. 2004;3(1):8.

115. Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, Lowe K. Management

of viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol. 2004;15(6):313-26.

116. Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, Lowe K. Management

of viral hepatitis: A Canadian consensus conference 2004. Can J Gastroenterol. 2004;18(12):715-28.

117. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Benhamou Y,

Messous D, Charlotte F, Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39(2):222-30.

118. Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D, Lee SS. Cardiac

hepatopathy: Clinical, hemodynamic and histological characteristics and correlations. Hepatology. 2003;37(2):393-400.

119. Thabut D, Simon M, Myers RP, Messous D, Imbert-Bismut F, Thibault V, Poynard T.

Noninvasive prediction of fibrosis in patients with chronic hepatitis C (Letter). Hepatology. 2003;37(5):1220-1.

120. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Ratziu V, Charlotte F,

Bricaire F, Katlama C, Poynard T. Serum biochemical markers accurately predict liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients. AIDS. 2003;17(5):721-5.

121. Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B infection on liver

histology and the response to antiviral therapy in chronic hepatitis C. J Viral Hepat. 2003;10(2):103-10.

122. Myers RP, Patel K, Pianko S, Poynard T, McHutchison J. The rate of fibrosis progression

is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat. 2003;10(1):16-22.

123. Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Mariné-Barjoan

E, Myers RP, Cacoub P. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France in 2001 (MORTAVIC 2001). AIDS. 2003;19(12):1803-9.



124. Poynard T, McHutchison JG, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology. 2003;38(2):481-92.

125. LeClerc S, Myers RP, Moussalli J, Cherin P, Herson S, Poynard T, Benveniste O.

Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med. 2003;14(4):237-43.

126. Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, et al. Reinforced

interferon alfa-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously non-responsive to interferon: A randomized trial. J Viral Hepat. 2003;10(3):197-204.

127. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, et al. A comparison of fibrosis progression in chronic liver diseases. The PANFIBROSIS Group. J Hepatol. 2003;38(3):257-65.

128. Myers RP, de Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Biochemical

markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count and the age-platelet index. Dig Dis Sci. 2003;48(1):146-53.

129. Myers RP. Meta-analysis of transarterial embolization in patients with unresectable

hepatocellular carcinoma (Letter). Radiology. 2003;227(2):611-12. 130. Myers RP, Abdo A, Poynard T. Pegylated interferon alfa for chronic hepatitis C (Protocol

for a Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.

131. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte

G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E, Myers RP, Poynard T. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol. 2003;1(1):3.

132. Myers RP, Poynard T. Interferon for interferon nonresponding and relapsing patients with

chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev. 2002;(4):CD003617.

133. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, Zarski JP, Poynard

T. Interferon for acute hepatitis C (Cochrane Review). Cochrane Database Syst Rev. 2002;(1):CD000369.

134. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, Zarski JP, Poynard

T. Interferon for chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev. 2002;(2):CD000370.

135. Thabut G, Thabut D, Myers RP, Bernard-Chabert B, Marrash-Chahla R, Mal H, Fournier

M. Thrombolytic therapy of acute pulmonary embolism: a meta-analysis. J Am Coll Cardiol. 2002;40(9):1660-7.

136. Myers RP, Ratziu V, Charlotte F, Imbert-Bismut F, Poynard T. Biochemical markers of

liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97(9):2419-25.



137. Cacoub P, Ratziu V, Myers RP, Ghillani P, Piette JC, Moussalli J, Poynard T. Impact of treatment on extra-hepatic manifestations in patients with chronic hepatitis C. The MULTIVIRC Group. J Hepatol. 2002;36(6):812-18.

138. Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, Myers RP, et al.

Interferon alpha plus ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002;46(12):3317-26.

139. Lebray P, Benhamou Y, Pol S, Myers RP, Poynard T, Di Martino V. NNRTI-related or –

unrelated hepatotoxicity (Letter)? Hepatology. 2002;36(2):512-13. 140. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, Ghillani P,

Charlotte F, Piette JC, Moussalli J. Fatigue in patients with chronic hepatitis C. The MULTIVIRC Group. J Viral Hepat. 2002;9(4):295-303.

141. Myers RP, Regimbeau C, Moussalli J, Ratziu V, Di Martino V, Thabut D, Bernard B, Benhamou Y, Poynard T. What are the indications for treatment of acute hepatitis C? Gastroenterol Clin Biol. 2002;26(Spec No 2):B188-93.

142. Myers RP, Shaffer EA, Beck PL. The prevalence, diagnosis and management of

gallbladder polyps. Can J Gastroenterol. 2002;16(3):187-194. 143. Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole.

Am J Gastroenterol. 2001;96(12):3428-31. 144. Myers RP, Swain, MG, Urbanski SJ, Lee SS. Reactivation of hepatitis Be antigen-negative

chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol. 2001;15(9):599-603.

145. Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in

Canadian patients with chronic hepatitis C. J Viral Hepat. 2001:8(4):249-55. 146. Myers RP, Downey D, Chakrabarthi S, Marotta PJ. Multiple focal nodular hyperplasia:

Atypical imaging characteristics. Can J Gastroenterol. 2001;15(2):137-42. 147. Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in

patients with chronic hepatitis C (see comments). Hepatology. 2000;31(4):834-9. 148. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transplant.

2000;6(4 Suppl 1):S44-52. 149. Myers RP, Chaudhary R, Fonseca K, Lee SS. Fatal hepatic decompensation in a patient

with hepatitis B cirrhosis following famciclovir withdrawal. Can J Gastroenterol. 2000;14(8)725-7

ii. Non-peer reviewed (Monographs) 1) Myers RP. Progression of fibrosis in patients with chronic hepatitis C. Advances in

Hepatitis C 2003;3(2):10-13.

iii. Book Chapters 1) Myers RP. Pericholangitis (Updated chapter). In: eMedicine.com (online textbook).

Zevitz M (ed.) eMedicine.com 2005.



2) Myers RP, Shaffer EA. Liver disease in pregnancy. In: First Principles of Gastroenterology (6th Edition). Thomson ABR, Shaffer EA (eds.). Canadian Association of Gastroenterology, 2004.

3) Shaffer EA, Myers RP. Liver structure and function. In: First Principles of Gastroenterology

(6th Edition). Thomson ABR, Shaffer EA (eds.). Canadian Association of Gastroenterology, 2004.

4) Myers RP, Poynard T. Infections with multiple hepatotropic viruses. In: Polymicrobial

Diseases. Brogden KA, Guthmiller JM (eds.). American Society for Microbiology Press 2001.

5) Myers RP, Swain MG. Pericholangitis. In: eMedicine.com (online textbook). Zevitz M (ed.) eMedicine.com 2001.

iv. Published Abstracts

1) Zenith L, Myers RP, Qamar H, Mansoor N, Carbonneau M, Gramlich L, Low G, Ma M, Tandon P. Severe muscle mass loss in cirrhosis – Can bedside tools be used to predict a CT or MRI diagnosis of Sarceponia? CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A;A34):82A.

2) Myers RP, Tanyingoh D, Shaheen A, Dixon E, Kaplan G. The Burden of Hepatitis C in Canada: A nationwide population based study. CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A; A40):84A.

3) Sadler M, Tanyingoh D, Myers RP, Ghosh S, Peck P, Kaplan G. Clinical outcomes in patients with Ischemic Colitis: A population based study. CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A;A9):73A.

4) James P, Kaplan G, Myers RP, Shaheen A, Hubbard J, Tinmouth J, Yong E, Love J, Heitman S. Mortality from acute pancreaticobiliary diseases requiring endoscopic retrograde cholangiopancreatography (ERCP) has decreased over time. CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A;A12):75A.

5) Pradhan F, Ladak F, Tracey J, Myers RP. Feasibility and reliability of the Fibroscan M and S2 (Pediatric) probes in small adults with chronic liver disease. CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A; A20):77A.

6) Oshiomogho J, Swain M, Coffin C, Lee S, Krajden M, Myers RP. The distribution of Interleukin-28B single nucleotide polymorphisms in Canadian patients with Hepatitis C Virus Genotype 1 CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A;A156):125A.

7) Coward S, Heitman S, Hubbard J, Proulx M, Panaccione R, Seow C, Leung Y, Ghosh S, Myers RP, Kaplan G. Ulcreative colitis associated hospitalization costs: A population-based study CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A;A13):75A.

8) Myers RP, Brogan A, Talbird S, Thompson J, Marcellin P, Jacobson I, DeMasi R, Menzie A, Yoshida E. Efficacy, safety, and cost-effectiveness in Canada of Telaprevir combination therapy by baseline fibrosis stage in treatmentnaive patients with chronic genotype 1 Hepatitis C virus infection. CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A;A45):86A.

9) Shaheen A, Myers RP, Barton J, Adams P. Prediction of longterm survival in patients with hereditary hemochromatosis CASL/CAG 2013 annual meeting. Can J Gastroenterol. 2013; 27(Suppl A;A5):72A.



10) Mathivanan M, Ladak F, Anton M, Kaplan G, Myers RP. The incidence of primary biliary cirrhosis: A systematic review and meta-analysis Can J Gastroenterol. 2012; 26(Suppl A;A217):145A.

11) Stinton L, Myers RP, Coffin C, Fritzler M. Autoantibodies directed against a Novel Cytoplasmic Compartiment (Rods and Rings) in Hepatitis C Infection Can J Gastroenterol. 2012;26(Suppl A;A311):176A.

12) Shaheen A, Kaplan G, Myers RP. Utility of quantifying internet search volume for the surveillance of common liver disorders. Can J Gastroenterol. 2012; 26(Suppl A;A218):145A.

13) Yoshida E, Kaita K, Myers RP, Sherman M, Bengtsson L, Adda N, Heathcote E. Telaprevir in combination with Peginterferon Alfa-2A and Ribavirin in Canadian patients with Chronic Genotype 1 HCV infection. Can J Gastroenterol. 2012;26(Suppl A;A319):179A.

14) Shaheen A, Tanyingoh D, Dixon E, Kaplan G, Myers RP. Medical injuries during hospitalization among patients with cirrhosis: A population-based study. Can J Gastroenterol. 2012;26(A45-Suppl A):88A.

15) Yarema MC, Johnson DW, Sivilotti MLA, Nettel-Aguirre A, Victorino C, DeWitt C, Gosselin S, Murphy N, Bailey B, Dong KA, Haney E, Purssell RA, Thompson M, Myers RP, et al. Long Live the King! Comparing Prognostic Markers in Acetaminophen Poisoning Fatalitie. Clin Toxicol. 2012;50:276-7.

16) Borman M, Pollet A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, Duarte-Rojo A, Wong D, Crotty P, Elkashab M, Myers RP. Detection and Quantification of Hepatic Steatosis using the Fatty Liver index: An external validation study. Can J Gastroenterol. 2012;26(A52 Suppl A):90A

17) Kareemi H, Coward S, Proulx M, Tanyingoh D, Quan S, Frolkis A, Dixon E, Myers RP, MacLean A, Brar S, Kaplan G. Comparing the incidence of perforated and non-perforated appendicitis: A validation and temporal trend study. Can J Gastro. 2012; 26(Suppl A;A212):143A.

18) Khorsheed S, Shaheen A, Burak K, Aspinall A, Myers RP, Martin S. Is the Model of End-Stage Liver Disease (MELD) a satisfactory predictor of pre-transplant mortality in the adolescent with chronic liver disease listed for liver transplantation? Can J Gastro. 2012;26(Suppl A;A305):175A.

19) Mathivanan M, Ladak F, Anton M, Kaplan G, Myers RP. The incidence of primary biliary cirrhosis: A systematic review and meta-analysis. Can J Gastro. 2012;26(Suppl A;A217):145A.

20) Shaheen A, Kaplan G, Myers RP. Utility of quantifying internet search volume for the surveillance of common liver disorders. Can J Gastro. 2012;26(Suppl A;A218):145A.

21) Shaheen A, Tanyingoh D, Dixon E, Kaplan G, Myers RP. Medical injuries during hospitalization among patients with cirrhosis: A population-based study. Can J Gastro. 2012;26(A45-Suppl A):88A.

22) Stinton L, Myers RP, Coffin C, Fritzler M. Autoantibodies directed against a Novel Cytoplasmic Compartiment (Rods and Rings) in Hepatitis C Infection. Can J Gastro. 2012;26(Suppl A;A311):176A.

23) Yarema MC, Johnson DW, Sivilotti MLA, Nettel-Aguirre A, Victorino C, DeWitt C, Gosselin S, Murphy N, Bailey B, Dong KA, Haney E, Purssell RA, Thompson M, Myers RP, Lord JA, Berlin RJ, Spyker DA, Rumack BH. Long Live the King! Comparing Prognostic Markers in Acetaminophen Poisoning Fatalities. Clin Toxicol. 2012;50:276-7.



24) Yoshida E, Kaita K, Myers RP, Sherman M, Bengtsson L, Adda N, Heathcote E. Telaprevir in combination with Peginterferon Alfa-2A and Ribavirin in Canadian patients with Chronic Genotype 1 HCV infection. Can J Gastro. 2012;26(Suppl A;A319):179A.

25) Asthana S, Burak KW, Bailey J, Myers RP, Meeberg G, Bain V, Mason A, Kneteman NM. Sirolimus-based immunosuppression is associated with improved sustained virologic response (SVR) to antiviral treatment for patients with recurrent hepatitis C (HCV) infection post-liver transplant (LT). Hepatology 2011;54(4 Suppl): A184.

26) Burak KW, Santodomingo-Garzon T, Swain MG, Lee SS, Urbanski SJ, Myers RP. Rituximab for Refractory Autoimmune Hepatitis: Final Results of A Phase 1 Study. J Hepatol 2011; 54 (Suppl 1): S507.

27) Myers RP, Faris P, Shaheen AAM, Aspinall AI, Meeberg G, Tandon P, Kneteman NM, Bain VG, Burak KW. Validation of the five-variable model for endstage liver disease (5vMELD) for predicting mortality on the liver transplant waiting list. Can J Gastroenterol 2011;25(Suppl A):A28.

28) Myers RP, Shaheen AAM, Burak KW, Dixon E. Early Clinical and Economic Outcomes of Living Liver Donors in the United States: A Population-Based Study. J Hepatol. 2011; 54 (Suppl 1):S215.

29) Myers RP, Shaheen AA, Faris PD, Aspinall AI, Burak KW. Modification of MELD and MELDNa to include serum albumin improves prediction of mortality on the liver transplant waiting list. Can J Gastroenterol. 2011;25 (Suppl A):A27.

30) Myers RP, Shaheen AAM, Faris P, Aspinall AI, Burak KW. Potential Survival Benefit of The 5-Variable Model For End-Stage Liver Disease (5vMELD) for Liver Transplant Allocation. J Hepatol. 2011;54 (Suppl 1):S215.

31) Myers RP, Tandon P, Ney M, Meeberg G, Faris PD, Shaheen AAM, Aspinall AI, Burak KW. Validation of the 5-variable model for end-stage liver disease (5vMELD) for predicting mortality on the liver transplant waiting list. Hepatology. 2011;54(4 Suppl):A624.

32) Lee SS, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, Hilzenrat N, Balshaw R, Usaty C, Myers RP. 36 versus 48 weeks of treatment with peginterferon alfa-2a plus ribavirin for genotype 2/4 patients with undetectable HCV RNA at week 8: Final results of a randomized multi-center study. Hepatology 2010;52(4 Suppl):359A.

33) Myers RP, Shaheen AA, Faris PD, Aspinall AI, Burak KW. Modification of MELD and MELDNa to include serum albumin improves prediction of mortality on the liver transplant waiting list. Hepatology 2010;52(4 Suppl):375A.

34) Kumagi T, Meaney C, Al-Harthy N, Acarsu U, Coltescu C, Myers RP, Hirschfield GM. The Toronto Western Hospital PBC Study: North American validation of biochemical predictors of long-term survival. Hepatology 2010;52(4 Suppl):482A.

35) Sasso MC, Myers RP, Elkashab M, Pomier-Layrargues G, Duarte-Rojo A, Wong DK, Beaton MD, Levstik MA, Kirsch R, Pollett A, Sandrin L, Miette V. CAP: A VCTE-guided tool for hepatic steatosis detection – preliminary results of a multi-center study in overweight and obese patients with chronic liver disease. Hepatology 2010;52(4 Suppl):647A.

36) Myers RP, Pomier-Layrargues G, Duarte-Rojo A, Wong DK, Beaton MD, Levstik MA, Kirsch R, Pollett A, Crotty P, Sasso MC, Landau M, Elkashab M. Performance of the FibroScan XL probe for liver stiffness measurement in obese patients: A multicenter validation study. Hepatology 2010;52(4 Suppl):1121A. * Poster of distinction.

37) Congly SE, Shaheen AA, Kaplan GG, Myers RP. The epidemiology and outcomes of amebic liver abscess: a population-based study of hospitalizations from 1993 to 2007. Hepatology 2010;52(4 Suppl):1245A.



38) Alnemer A, Shaheen AA, Swain M, Myers RP. The sleeping giant has awoken: An assessment of the burden of Hepatitis C in the United States between 1993 and 2007. Can J Gastro. 2010;24(Suppl A:1A-200A;A73):91A.

39) Bailey J, Myers RP, Aspinall A, Coffin C, Lusina B, Schindel L, Klein P, Drinnan T, Burak K. Influence of immunosuppression and other predictors of sustained virologic response in recurrent Hepatitis C infection following liver transplantation. Can J Gastro. 2010;24(Suppl A:1A-200A;A157):120A.

40) Bailey J, Shaheen AA, Hubbard J, Kaplan G, Myers RP. The impact of waiting for emergent endoscopic procedures on mortality and resource utilization in patients with gastrointestinal disorders. Can J Gastro. 2010;24(Suppl A:1A-200A;A55):85A.

41) Burak K, Shaheen AA, Aspinall A, Myers RP. Increased mortality on the liver transplant waiting list in females under the MELD allocation sytem may be eliminated by considering estimated glomerular filtration rate. Can J Gastro. 2010;24(Suppl A:1A-200A;A19):70A.

42) Congly S, Shaheen AA, Kaplan G, Myers RP. The epidemiology and outcomes of Amebic Liver Abscess: A population-based study of hospitalizations from 1993 to 2007. Can J Gastro. 2010;24(Suppl A:1A-200A;A180):128A.

43) Crespin M, Ma C, Proulx M, DeSilva S, Pruscinkewicz M, Seow C, Panaccione R, Ghosh S, Hubbard J, Myers RP, Kaplan G. Validity of administrative data in identifying in-hospital complications in ulcerative colitis patients undergoing colectomy. Can J Gastro. 2010;24(Suppl A:1A-200A;A9):68A.

44) Lee S, Heathcote J, Kaita K, Myers RP, Sherman M, Anderson F, et al. Three years of Tenofovir Disoproxil Fumarate (TDF) treatment in HBEAG-negative and positive patients with chronic Hepatitis B. Can J Gastro. 2010;24(Suppl A:1A-200A;A20):71A.

45) Liaw YF, Raptopoulou-Gigi H, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Tsai N, Bialkowska J, Tang S, Cooney E. Risk and Predictors of mortality or Hepatocellular Carcinoma among Entecavir- or Adefovir-Treated Chronic Hepatitis B patients with evidence of Hepatic decompensation. Journal of Hepatology. 2010; Supplement 1, vol. 52(1011):S390-91.

46) Myers RP, Heathcote J, Lee S, Kaita K, Sherman M, Anderson F, et al. Resistance surveillance in HBEAG + and HBEAG-Hepatitis B patients treated with Tenofovir DF (TDF) for up to 144 weeks. Can J Gastro. 2010;24(Suppl A:1A-200A;A268):157A.

47) Myers RP, Shaheen AA, Aspinall AI, Quin RR, Burak KW. Increased mortality on the liver transplant waiting list in females under the meld allocation system: Utility of revised MELD incorporating estimated glomerular filtration rate. Journal of Hepatology. 2010;Supplement 1, vol. 52(52):S24-25.

48) Yarema MC, Shaheen AAM, Myers RP. Trends in the epidemiology of acetaminophen overdose in the United States: a population-based study. Can J Emerg Med. 2010;12(3):248.

49) Yarema MC, Shaheen AAM, Myers RP. Outcomes of acetaminophen overdose in the United States: A population-based study of hospitalizations between 1993 and 2007. Can J Emerg Med. 2010;12(3):252.

50) Coffin CS, Shaheen AA, Burak K, Myers RP. Pregnancy outcomes among liver transplant recipients in the United States: A nation-wide case-control analysis. Hepatology. 2009;50(4 Suppl:1A-1246A;40):321A.

51) Coffin CS, Shaheen AA, Kaplan G, Myers RP. Hospitalization trends for HIV Positive patients coinfected with Hepatitis B (HBV) or Hepatitis C Virus (HCV): A population-based study from 1993 to 2005. Hepatology. 2009;50(4 Suppl:1A-1246A;1338):921A.



52) Cooper C, Robert J, Feinman V, Elkashab M, Anderson F, Scully L, Doucette K, Witt-Sullivan H, Bailey R, Myers RP, et al. Outcomes of a large inclusive population-based Hepatitis C treatment program are similar to randomized controlled trials: Interim results of the Canadian Redipen Program. Hepatology. 2009;50(4 Suppl:1A-1246A;850):703A.

53) Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Myers RP, et al. Efficacy and safety of Entecavir versus Adefovir in chronic Hepatitis B patients with evidence of Hepatic decompensation. Hepatology. 2009;50(4 Suppl:1A-1246A;422):505A.

54) Liu MF, Dean S, Myers RP, Shaheen AA, Faris P, Jette N, Quan H. Prevalence variations in selected gastric and liver disease among ethnic populations. Am J Epi. 2009;169:S78.

55) Shaheen AA, Kaplan GG, Hubbard JN, Myers RP. The impact of waiting for emergent endoscopic procedures on mortality and resource utilization in patients with gastrointestinal disorders. Gastrointestinal Endoscopy. 2009;69(5):AB211.

56) Burak KW, Williamson-Coffey S, Swain MG, Lee SS, Cole S, Urbanski SJ, Myers RP. Rituximab for refractory autoimmune hepatitis: Interim results of a phase 1 study. Hepatology. 2008;48(4 Suppl):1093A.

57) Heathcote J, Marcellin P, Kaita K, Lee S, Myers RP, Sherman M, Sorbel J, Anderson J, et al. Tenofovir DF (TDF) showed superior antiviral efficacy to Adefovir Dipivoxil in two pivotal, randomized, double-blind, studies for the treatment of HBEUG-negative and HBEUG-positive chronic hepatitis B (CHB): Study 102 and Study 103. Can J Gastro. 2008;22(Suppl A):78A.

58) Marcellin P, Buti M, Krastev Z, Gurel S, Balabanska RI, Dusheiko G, Myers RP, Heathcote EJ, Sorbel J, Anderson J, Mondou E, Rousseau F. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (Study 102): Preliminary analysis. Hepatology. 2008;48(4 Suppl):370A.

59) Meddings L, Myers RP, Shaheen AA, Laupland KB, Hubbard J, Kaplan G. Predictors of mortality due to pyogenic liver abscesses: An analysis of U.S. hospitalizations from 1998-2004. Can J Gastro. 2008;22(Suppl A):163A.

60) Myers RP, Coffin CS, Gao ZH, Shaheen AA, Crotty PM, Vogel HJ, Weljie AM. A metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C. Hepatology. 2008;48(4 Suppl):353A.

61) Myers RP, Kaplan GG, Shaheen AA. Weekend versus weekday admission and mortality from esophageal variceal bleeding. Hepatology. 2008;48(4 Suppl):630A.

62) Myers RP, Papay KD, Shaheen AA, Kaplan GG. The relationship between hospital volume and outcomes of esophageal variceal bleeding. J Hepatol. 2008;48(Suppl 2):S120.

63) Myers RP, Liu MF, Shaheen AA. The burden of hepatitis C virus infection is growing: A Canadian population-based study of hospitalizations from 1994-2004. Can J Gastro. 2008;22(Suppl A):75A.

64) Myers RP, Marotta PJ, Anderson F, Lalonde R, Manchanda T. Health outcomes in patients with chronic hepatitis C treated in community versus academic centres: Week 12 results of the approach study. Can J Gastro. 2008;22(Suppl A):144A.

65) Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: A population-based study including 4,275 biopsies. Can J Gastro. 2008;22(Suppl A):162A.

66) Papay KD, Kaplan GG, Shaheen AA, Myers RP. Impact of hospital volume on outcomes in patients with esophageal variceal bleeding: An analysis of the U.S. Nationwide Inpatient Sample from 1998 to 2004. Can J Gastro. 2008;22(Suppl A):119A.



67) Robbins SJ, Shaheen AA, Liu MF, Myers RP. Is the burden of alcoholic liver disease changing? A Canadian epidemiologic study of hospitalizations from 1994-2004. Can J Gastro. 2008;22(Suppl A):161A.

68) Shaheen AA, Hubbard JN, Mason AL, Swain MG, Kaplan GG, Myers RP. The burden of primary biliary cirrhosis (PBC) in the United States: A population-based study of hospitalizations from 1993 to 2005. Hepatology. 2008;48(4 Suppl):795A.

69) Shaheen AA, Kaplan GG, Myers RP. Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: An analysis of U.S. hospitalizations from 1998-2004. Can J Gastro. 2008;22(Suppl A):164A.

70) Shaheen AA, Kaplan GG, Myers RP. Morbidity and mortality following coronary artery bypass graft (CABG) surgery in patients with cirrhosis: A population-based study. J Hepatol. 2008;48(Suppl 2):S39.

71) Bzowej N, Marcellin P, Chan HLY, Lai CL, Cho M, Heathcote EJ, Moon YM, Chao YC, Myers RP, et al. A randomized trial of telbivudine vs. adefovir for HBeAg-positive chronic hepatitis B: Efficacy through week 76, predictors of response and effects of switching to telbivudine. Gastroenterology. 2007;132(4 Suppl 2):A764.

72) Leung Y, Li B, Myers RP. Impact of alcohol abuse, liver disease, and unintentional ingestions on the outcome of acetaminophen overdose: A population-based case-control study. Gastroenterology. 2007;132(4 Suppl 2):A774.

73) Marcellin P, Chan HLY, Lai CL, Cho M, Moon YM, Chao YC, Heathcote EJ, Myers RP, et al. 76 Week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine. J Hepatol. 2007;46(Suppl 1):S55.

74) Marcellin P, Chan HLY, Lai CL, Cho M, Heathcote EJ, Moon YM, Chao YC, Myers RP, et al. In hepatitis B patients treated with either adefovir or telbivudine, maximal early HBV suppression at 24 weeks predicts optimal one-year efficacy. J Hepatol. 2007;46(Suppl 1):S193.

75) Myers RP, Shaheen AA, Swain MG, Lee SS, Cole S, Coffey-Williamson S, Burak KW. Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA). Hepatology. 2007:46(Suppl 1):550A.

76) Myers RP, Li B, Fong A, Shaheen AA, Quan H. Hospitalizations for acetaminophen overdose: A Canadian population-based study. Can J Gastro. 2007;21(Suppl A):125A.

77) Myers RP, Li B, Dean S, Shaheen AA, Quan H. Impact of alcohol abuse, liver disease and unintentional overdoses on outcomes of acetaminophen overdose: A population based study. Can J Gastro. 2007;21(Suppl A):111A.

78) Shaheen AA, Myers RP. Diagnostic accuracy of the APRI for the prediction of hepatitis C-related fibrosis: A systematic review. Hepatology. 2007:46(Suppl 1):833A.

79) Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy. J Hepatol. 2007;46(Suppl 1):S212.

80) Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy. Can J Gastro. 2007;21(Suppl A):154A.

81) Shaheen AA, Myers RP. Systematic review of the diagnostic accuracy of fibrosis marker panels and transient elastography in patients with HIV/hepatitis C coinfection. Can J Gastro. 2007;21(Suppl A):75A.



82) Alqahtani S, Federico P, Myers RP. Valproate-related hyperammonemic encephalopathy: A condition of which all hepatologists should be aware. Can J Gastro. 2006;20(3):193.

83) Burak KW, Meeburg G, Myers RP, Hilsden RJ, Swain MG, Wong WW, Fick GH, Bain VG, Kneteman NM. Should Canada adopt the MELD score for allocation of liver transplants? Can J Gastro. 2006;20(3):194.

84) Bzowej N, Chan HLY, Lai CL, Cho M, Moon YM, Chao YC, Heathcote EJ, Myers RP, et al. A randomized trial of telbivudine (LdT) vs. adefovir for HBeAg-positive chronic hepatitis B: Final week 52 results. Hepatology. 2006;44(4 Suppl 1):563A.

85) Chan H, Lai CL, Cho M, Heathcote J, Moon Y-M, Chao Y-C, Myers RP, Minuk G, Marcellin P, Chuttaputti A, Jeffers L, Sievert W, Kaiser R, Chao G, Brown N, and the 018 Study Group. A randomized trial of telbivudine (LdT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis. J Hepatol. 2006;44(Suppl 2):S24-5.

86) Heathcote EJ, Chan H, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk G, Marcellin P, Jeffers L, Sievert W, Kaiser R, Chao G, Brown N, and the 018 Study Group. A randomized trial of telbivudine (LdT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis. Gastroenterology. 2006;130(4 Suppl 2):765A.

87) Kaila B, Myers RP. Discordant presentation of autoimmune hepatitis in twins. Canadian Association of Gastroenterology. 2006;20(3):A181.

88) Kaplan GG, Heitman SJ, Hilsden RJ, Urbanski SJ, Lee SS, Burak KW, Myers RP, Swain MG, Panaccione R. Population-based cost analysis of screening for dysplasia in pimary sclerosing cholangitis. Gastroenterology. 2006;130(4 Suppl 2):652A.

89) Krongold PH, Myers RP, Dixon E, Hughes R, Johnson C, Nash CL.Novel ALK-1 mutation in a patient with mesenteric steal due to hereditary hemorrhagic telangiectasia. Canadian Association of Gastroenterology. 2006;20(3):A185.

90) Myers RP, Li B, Fong A, Shaheen AA, Quan H. Temporal trends and risk factors for acetaminophen overdose: A Canadian population-based study. Hepatology. 2006;44(4 Suppl 1):372A.

91) Myers RP, Fong A, Swain MG, Quan H. The incidence of primary biliary cirrhosis (PBC) is rising: A Canadian population-based study. Hepatology. 2006;44(4 Suppl 1):635A.

92) Myers RP, Fong A, Swain MG, Quan H. High incidence of primary biliary cirrhosis (PBC) in southern Alberta: A population-based study. Can J Gastro. 2006;20(3):205.

93) Yan BM, Nash C, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer: A meta-analysis. Canadian Association of Gastroenterology. 2006;20(3):A139.

94) Al-Enezi B, Messous D, Imbert-Bismut F, Poynard T, Myers RP. Association between serum leptin, metabolic factors and liver histological lesions in patients with chronic hepatitis C. Canadian Association for the Study of the Liver 2005.

95) Burak KW, Meeburg G, Myers RP, Hilsden RJ, Swain MG, Wong WW, Fick GH, Bain VG, Kneteman NM. Should Canada adopt the MELD score for allocation of liver transplants? Hepatology. 2005;42(4 Suppl 1):322A.

96) Kaplan GG, Heitman SJ, Hilsden RJ, Urbanski SJ, Lee SS, Burak KW, Myers RP, et al. Screening for dysplasia in primary sclerosing cholangitis: A population-based assessment of physician practices. Amercian College of Gastroenterology 2005.

97) Marotta PJ, Myers RP, Jacobs P, Adams J. A Canadian economic evaluation of Pegasys/RBV™ (peginterferon alfa-2a and ribavirin) for the treatment of chronic hepatitis C. Canadian Association for Population Therapeutics 2005.



98) Aspinall AI, Myers RP, Marotta PJ, Jacobs P, Adams J. A Canadian economic evaluation of Pegasys® (Peginterferon-α2a[40kD]) in treatment-naïve patients chronically infected with hepatitis C. The Canadian Association for Population Therapeutics 2004.

99) Myers RP, Benhamou Y, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on histological lesions in HIV and hepatitis C virus-coinfected patients. Conference Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections 2003, Boston, MA.

100) Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, Poynard T. The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C: Prospective validation in 534 patients. Hepatology. 2002;36(4 Pt 2):351A.

101) Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, Poynard T. Life is possible without biopsy in patients with chronic hepatitis C: Validation of biochemical markers of liver fibrosis and activity in 1570 patients and blood donors. Hepatology. 2002;36(4 Pt 2):351A.

102) Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Benhamou Y, Messous D, Poynard T. Noninvasive prediction of histologic lesions using serum biochemical markers in patients with chronic hepatitis B. Hepatology. 2002;36(4 Pt 2):609A.

103) Myers RP, Benhamou Y, Bochet M, Mehri D, Di Martino V, Valantin MA, Katlama C, Bricaire F, Poynard T. Pegylated interferon alfa-2b and ribavirin in HIV/HCV-coinfected patients. Hepatology. 2002;36(4 Pt 2):575A.

104) Myers RP, Benhamou Y, Bochet M, Mehri D, Di Martino V, Valantin MA, Katlama C, Bricaire F, Poynard T. Pegylated interferon alfa-2b and ribavirin in HIV/HCV-coinfected patients. Hepatology. 2002;36(4 Pt 2):575A.

105) Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B virus (HBV) infection on liver histology and the response to antiviral therapy in chronic hepatitis C. Hepatology. 2002;36(4 Pt 2):587A.

106) Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, Poynard T. La vie sans biopsie hépatique est possible chez les maladies ayant une hépatite chronique C: Validation des marqueurs biochimiques de la fibrose et de l’activité chez 1,570 malades et donneurs du sang. Gastroenterol Clin Biol. 2002;26(H.S. 3):C029.

107) Myers RP, Benhamou Y, Bochet M, Imbert-Bismut F, Thibault V, Ratziu V, Charlotte F, Katlama C, Poynard T. Evaluation de la fibrose hépatique par des marqueurs biochimiques chez les patients co-infectés par le VIH et le VHC. Gastroenterol Clin Biol. 2002;26(H.S. 1):A104.

108) Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Ratziu V, Charlotte F, Bricaire F, Katlama C, Poynard T. Serum biochemical markers accurately predict liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients. J Hepatol. 2002;36(Suppl 1):18.

109) Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Ratziu V, Charlotte F, Bricaire F, Katlama C, Poynard T. Serum biochemical markers accurately predict liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients. Gastroenterology. 2002;122(4 Suppl 1):528.

110) Myers RP, Patel K, Pianko S, Poynard T, McHutchison J. The rate of fibrosis progression is an independent predictor of response to antiviral therapy in chronic hepatitis C. Gastroenterology. 2002;122(4 Suppl 1):T1411.



111) Poynard T, Myers RP, McHutchison J, Manns M, Imbert-Bismut F, Albrecht J, D’Arondel C. Biochemical markers of sustained response in HCV patients treated with pegylated interferon alfa-2b and ribavirin. Hepatology. 2002;36(4 Pt 2):592A.

112) Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: An example in a randomized trial of pegylated interferon alfa-2b and ribavirin combination. Hepatology. 2002;36(4 Pt 2):351A.

113) Taieb J, Chollet-Martin S, Myers RP, Delarche C, Cohrad M, Lebeaut A, Garaud JJ, Bernard B, Gougerot-Pochidalo MA, Poynard T. Subcutaneous recombinant interleukin-10 (RHU IL-10) plus corticosteroids in the treatment of severe alcoholic hepatitis: A pilot study. Hepatology. 2002;36(4 Pt 2):477A.

114) Burak KW, Myers RP, Swain MG. Beneficial effect of adding methotrexate for primary biliary cirrhosis patients with partial response to ursodeoxycholic acid monotherapy. Hepatology. 2001;32(4 Pt 2).

115) Myers RP, Al-Amji M, Gregor JC, Marotta P. Cost-effectiveness of cytomegalovirus (CMV) prophylaxis in high-risk donor-positive, recipient-negative liver transplant recipients. Conference Proceedings of the Canadian Society for Transplantation Meeting 2001, Lake Louise, Alberta.

116) Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D, Lee SS. Cardiac hepatopathy: Clinical, Hemodynamic and histological characterization of 90 patients. Hepatology. 2001;32(4 Pt 2):691.

117) Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. Gastroenterology. 2000;118(4 Suppl 2):A953.

118) Myers RP, Gregor JC, McDonald JWD, Panaccione R, Feagan BG. Health-related quality of life in Crohn's disease: whose preferences should we use? Gastroenterology. 2000;118(4 Suppl 2):A214.

119) Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Can J Gastroenterol. 2000;14(Suppl A):24A.

120) Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Gastroenterology. 1999;116(4 Part 2):A1252.

121) Myers RP, Gregor JC, Panaccione R, Gilmore PS, Hopkins MB, Vandervoort MK, McDonald JWD, Feagan BG. Quality of life in Crohn’s disease: Perceptions of physicians. Gastroenterology. 1999;116(4 Part 1):A780.

122) Myers RP, Gregor JC, Panaccione R, Gilmore PS, Hopkins MB, Vandervoort MK, McDonald JWD, Feagan BG. Quality of life in Crohn’s disease: Perceptions of the public. Gastroenterology. 1999;116(4 Part 2):A781.

123) Myers RP, Gregor JC, McDonald JWD, Panaccione R, Feagan BG. Quality of life in Crohn's disease: utility in the eye of the beholder? Conference Proceedings of Canadian Digestive Diseases Week / PanAmerican Congress of Gastroenterology 1999, Vancouver, British Columbia.

v. Oral Presentations of Research at Conferences

Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Increased mortality on the liver transplant waiting list in females under the MELD allocation system: Utility of revised MELD incorporating estimated glomerular filtration rate. • European Association for the Study of the Liver, Vienna, Austria, April 16, 2010.



Burak KW, Shaheen AA, Aspinall AI, Myers RP. Increased mortality on the liver transplant waiting list in females under the MELD allocation system may be eliminated by considering estimated glomerular filtration rate. • Canadian Digestive Diseases Week/The Canadian Association for the Study of the Liver,

Toronto, ON, 2010.

Myers RP, Coffin CS, Gao ZH, Shaheen AA, Crotty PM, Vogel HJ, Weljie AM. A metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C. • American Association for the Study of Liver Diseases, San Francisco, California, 2008.

Myers RP, Shaheen AA, Kaplan GG. Weekend versus weekday admission and mortality from gastrointestinal hemorrhage due to peptic ulcer disease. • American College of Gastroenterology, Orlando, Florida, 2008.

Myers RP, Papay KD, Shaheen AA, Kaplan GG. The relationship between hospital volume and outcomes of esophageal variceal bleeding. • American Gastroenterological Association Digestive Diseases Week, San Diego,

California, 2008.

Shaheen AA, Kaplan GG, Myers RP. Morbidity and mortality following coronary artery bypass graft (CABG) surgery in patients with cirrhosis: A population-based study. • European Association for the Study of the Liver, Milan, Italy, 2008.

Myers RP, Liu MF, Shaheen AA. The burden of hepatitis C virus infection is growing: A Canadian population-based study of hospitalizations from 1994-2004. • Canadian Association for the Study of the Liver, Montreal, Quebec, 2008.

Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Ratziu V, Charlotte F, Bricaire F, Katlama C, Poynard T. Serum biochemical markers accurately predict liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients. • European Association for the Study of the Liver, Madrid, Spain, 2002 • American Gastroenterological Association Digestive Diseases Week, San Francisco,

California, 2002. Myers RP, Al-Ajmi M, Gregor JC, Marotta P. Cost-effectiveness of cytomegalovirus (CMV) prophylaxis in donor-positive, recipient-negative liver transplant recipients. • Canadian Society for Transplantation, Lake Louise, Alberta, 2001.

Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Can J Gastroenterol. 2000;14(Suppl A):24A. • *Canadian Digestive Diseases Week, Quebec City, Quebec, 2000.

i. biographical data name robert paul myers...

Documents